The average pair of prescription glasses in the United States costs $200–$300, but an identical pair manufactured abroad for $15 will be marked up 1,000% before you buy it. Vision care has become financially inaccessible to tens of millions of Americans not because of medical necessity, but because a single corporation controls 80% of global eyewear production and faces zero regulatory consequences for price-fixing. The result: a generation of Millennials and Gen Z going without corrective lenses entirely, failing vision screenings, missing job opportunities, and suffering preventable eye damage.
Key Takeaways: Eyeglasses cost $200–$300 with 1,000% retail markup. EssilorLuxottica controls 80% global eyewear production. LASIK $2,000 in US vs $700 in Mexico. Contact lenses $180–$1,200 annually. Medicare doesn’t cover eye exams or glasses. Vision insurance is a bad deal. EssilorLuxottica defeated antitrust lawsuits Sept 2025. FTC too weak to enforce. Online retailers offer some relief but don’t solve monopoly. Targets Boomer retirees and younger patients without alternatives.
Why Are Eyeglasses So Expensive? The 1,000% Markup That Boomers Let Happen
A pair of prescription glasses costs roughly $15–30 to manufacture in Vietnam, China, or India. Frames, lenses, coatings, labor, shipping—everything. A retailer purchases that pair wholesale for $50–70. They then sell it to you for $200–600. That’s not a profit margin. That’s a scam, and it’s been legal since the Reagan administration stopped enforcing antitrust law.
The markup works because the eyewear industry has consolidated into a single vertical monopoly. EssilorLuxottica doesn’t just own Ray-Ban and Oakley frames; it also owns the companies that make the lenses (Essilor, Varilux), the retailers that sell them (LensCrafters, Sunglass Hut, Pearle Vision), the vision insurance plans (60% of all US vision plans), and the labs that cut the lenses. When you walk into what you think is a competitor store, you’re still buying from the same parent company.
Result: there is no price competition. A $200 pair of Ray-Bans costs 4x more than a $50 pair at Costco because the brand is owned by a monopoly. Designer frames (Chanel, Dolce & Gabbana, Prada) are manufactured by EssilorLuxottica under license, marked up 800–1,000%, and sold by EssilorLuxottica retailers. The company captures the entire supply chain and the entire profit.
How Medicare Got Trapped Into Subsidizing a Monopoly (While Covering Nothing for Retirees)
Medicare doesn’t cover routine eye exams or prescription glasses. In 2024, the average American over 65 paid $200–500 out-of-pocket for an annual eye exam. Another $300–500 for replacement glasses. For a population on fixed incomes (average Social Security: $1,907/month), that’s 3–5% of monthly income spent on vision care. Multiplied across 45 million Medicare beneficiaries, that’s $13.5–22.5 billion in annual out-of-pocket vision costs.
But here’s the twist: Medicare does subsidize the eyewear monopoly through supplemental insurance. Medigap plans (purchased by 27% of Medicare beneficiaries) cover some vision care, but coverage is capped. Vision insurance plans sold to retirees offer $150–200/year in eyeglasses allowances while charging $100–300/year in premiums—a net loss for the consumer. The real beneficiary is EssilorLuxottica, which captures both the inflated retail prices and the supplemental insurance payments. The poorest seniors—those who can’t afford supplemental insurance—pay full retail.
The LASIK Trap: Why One Eye Costs More Than a Used Car Down Payment
LASIK eye surgery costs approximately $2,000 per eye in the United States. The same surgery in Mexico costs $700–1,000 per eye. In Canada, it’s $1,200 per eye. The price gap isn’t explained by labor costs or equipment. The gap is explained by monopoly. In the US, LASIK is dominated by a handful of chains owned by or affiliated with EssilorLuxottica. There’s no price competition.
The result: LASIK remains inaccessible to most working-class Americans. A procedure that costs $4,000 for both eyes is out of reach for someone making $40,000/year. Someone with myopia who can’t afford LASIK is forced into a lifetime of glasses and contacts, paying $10,000–30,000 over 30 years instead of $4,000 once. That’s the logic of the monopoly: make the permanent solution so expensive that consumers are forced into recurring subscription purchases.
Contact Lenses: The Disposable Market That Generates Recurring Revenue
Contact lenses are the eyewear industry’s recurring revenue stream. A manufacturer can produce a daily disposable contact lens for approximately $0.12 per lens. Retailers mark it up to $0.50–1.25 per lens. A patient wearing daily disposables pays $50–75/month, or $600–900/year, for a product that costs $3.60/month to manufacture. That’s a 13x markup on a product with replacement demand built in.
Contact lens prices have risen 20–30% in the past five years while manufacturing costs have fallen. Insurance coverage is inconsistent: some plans cover $100–150/year, but the full annual cost is $600–900. Multiply by 25 million contact lens wearers in the US, and you’re looking at $475 billion in cumulative monopoly extraction from a single product category. Gen Z has increasingly rejected contacts due to cost, choosing to go without or rationing use only to weekends. Preventable eye complications increase as a result.
The Antitrust Failure: How EssilorLuxottica Defeated Consumer Lawsuits and Laughed All the Way to the Bank
In September 2025, EssilorLuxottica defeated consumer antitrust lawsuits alleging monopoly pricing and market foreclosure. A federal judge dismissed the case, ruling that the plaintiffs had not sufficiently alleged a “plausible claim” of antitrust violation. The FTC, which should have blocked the merger that created EssilorLuxottica in the first place, did nothing.
This is the story of modern antitrust enforcement: a corporation acquires enough market share to control prices, consumers sue, and courts rule that controlling 80% of the market isn’t “plausible” evidence of monopoly power. The merger that created modern EssilorLuxottica happened in 2018, when Essilor acquired Luxottica. This should have been blocked on vertical integration grounds—a single company controlling both the inputs and the outputs and the distribution. But the FTC under Trump didn’t challenge it. By the time Democratic administrations took over, consolidation was too complete to unwind. Result: zero consequences for monopoly behavior.
The Insurance Smoke Screen: Why Vision Insurance Isn’t Actually Insurance
Vision insurance is a misnomer. Real insurance pools risk and pays for unexpected costs. Vision insurance is a discount plan that makes consumers feel covered while actually capturing price increases. A plan charges $100–300/year in premiums for $150–200/year in glasses allowances. The net result: the patient subsidizes the insurance company’s marketing while the insurance company’s parent (EssilorLuxottica) captures both the inflated retail prices and the supplemental insurance payments. This is the definition of a monopoly using insurance as a tool to disguise price-fixing.
The Counter-Argument: Aren’t Online Glasses and Discount Retailers Enough?
Fair point: online retailers like Warby Parker and Zenni have disrupted the premium market. But they haven’t solved the systemic monopoly. Online retailers still require an eye exam (optometrists often hostile to cheap alternatives), offer budget lenses that degrade faster, can’t touch specialty markets (bifocals, progressives, high-index), and have done nothing to disrupt LASIK or contacts. Patients with complex prescriptions are trapped in the premium market. The average American paying $200–300 for glasses has just been told they’re getting a good deal compared to a $500 designer frame—but it’s still 10x the manufacturing cost.
FAQ: How to Navigate Vision Care Without Getting Fleeced
Q: What’s the real cost of glasses? Manufacturing cost is $15–30. Retail is $200–600. If you’re paying more than $100 for basic single-vision glasses, you’re overpaying. Buy online (Zenni, Warby Parker, Costco) unless you have a complex prescription or tight timeline.
Q: Should I buy vision insurance? Only if it’s bundled into your health plan at no extra cost. Standalone plans are a bad deal: $100–300 premiums for $150–200 benefits. Buy it yourself instead: set aside $200–300/year and buy one pair every 2–3 years.
Q: Is LASIK worth it? At $4,000/eye in the US, no—unless you can’t afford replacing glasses every 2 years. Fly to Mexico, get LASIK for $700–1,000/eye, and save $2,000–2,600. Otherwise, wait for the technology to become commodified (10–15 years) and prices to fall.
Q: What if I can’t afford any of this? Contact your state’s health department for vision screening and referrals to charity programs (Vision to Learn, New Eyes, Lions Club). Don’t go without corrective lenses; untreated myopia leads to eye damage and injuries far more costly than the glasses themselves.
Q: When will prices fall? Not until the FTC enforces antitrust law or Congress breaks up EssilorLuxottica. Millennial and Gen Z voters will have to demand change. It’s the only path forward.
Sources & Methodology
Vision Care Costs: Glasses.com (Jan 2026), Warby Parker (2026), Vox Chavie Lieber (Mar 2019, updated Feb 2026), MyEyeBB (Feb 2026), MyMedicineAdvisor Dr. Olivia Brown (Feb 2026).
EssilorLuxottica Antitrust: Reuters (Sept 26, 2025), MLex (Sept 2025), PYMNTS (Sept 28, 2025), Consumer Watchdog (Jan 2019, updated 2026).
Medicare & Insurance: The Big 65 (Mar 2026), Paul Bininsurance (Feb 2026).
International Price Comparisons: SurgeryCostGuide (2026), Docternist (Jan 2026).
